Site Map
Product Pages Catalogue Numbers 1401 - 1500
| Cat. No. | Product Name & Pharmacological Action |
|---|---|
| 1401 | NU 1025 |
| Potent PARP inhibitor | |
| 1402 | SB 203580 hydrochloride |
| Selective inhibitor of p38 MAPK; water-soluble | |
| 1403 | FPL 64176 |
| Potent activator of L-type Ca2+ channels | |
| 1405 | (-)-Terreic acid |
| Selective inhibitor of BTK | |
| 1406 | Trichostatin A |
| Histone deacetylase inhibitor | |
| 1407 | PP 2 |
| Potent, selective Src inhibitor | |
| 1408 | YM 022 |
| Highly potent, selective non-peptide CCK2 antagonist | |
| 1409 | CGP 39551 |
| Potent, selective and competitive NMDA antagonist. Brain penetrant in vivo | |
| 1410 | SDM25N hydrochloride |
| Potent, selective non-peptide δ antagonist | |
| 1411 | Noladin ether |
Endogenous agonist for CB1 |
|
| 1412 | Chromanol 293B |
| IKs blocker. Also blocks ICFTR | |
| 1413 | NAS-181 |
| Selective r5-HT1B antagonist. Active in vivo | |
| 1414 | Scopolamine hydrobromide |
Non-selective muscarinic antagonist |
|
| 1415 | 1400W dihydrochloride |
| Potent, highly selective iNOS inhibitor | |
| 1416 | Homoharringtonine |
| Inhibitor of protein synthesis. Antileukemic agent | |
| 1417 | Daidzein |
| Arrests cell cycle in G1 phase | |
| 1418 | Resveratrol |
| Cyclooxygenase inhibitor | |
| 1419 | Naloxone benzoylhydrazone |
| κ3 agonist. Antagonist at μ, δ, κ1 and ORL1 | |
| 1420 | D-myo-Inositol-1,3,4,5-tetrakisphosphate, octapotassium salt |
| Potent inhibitor of Ins(1,4,5)P3 5-phosphatase. Metabolite of Cat. No. 1482 | |
| 1421 | MAFP |
Potent, irreversible anandamide amidase inhibitor |
|
| 1422 | DCEBIO |
| Activates Cl- conductance and hIK1 K+ channels | |
| 1425 | (S)-(+)-Dimethindene maleate |
M2-selective antagonist |
|
| 1426 | PPT |
| Subtype-selective ERα agonist | |
| 1427 | Citalopram hydrobromide |
| Highly potent and selective 5-HT uptake inhibitor | |
| 1428 | Amyloid β-Peptide (1-42) (human) |
| Predominant amyloid β-protein fragment | |
| 1429 | Amyloid β-Peptide (25-35) (human) |
| Human amyloid β-protein fragment functionally required for neurotoxicity | |
| 1430 | DuP 697 |
| Cyclooxygenase (COX-2) inhibitor | |
| 1431 | DPDPE |
| δ-receptor agonist | |
| 1435 | SQ 22536 |
| Adenylyl cyclase inhibitor | |
| 1437 | D609 |
| Selective PC-PLC inhibitor | |
| 1439 | Ruthenium Red |
| Non-selective Ca2+ channel blocker (N- and P-type) | |
| 1440 | BMY 14802 hydrochloride |
| Sigma antagonist. Antipsychotic agent | |
| 1441 | BMS 182874 hydrochloride |
| Highly selective, orally active non-peptide ETA antagonist | |
| 1442 | BMY 45778 |
| Non-prostanoid prostacyclin IP receptor partial agonist | |
| 1443 | Metastin (human) |
| Potent, endogenous ligand for KISS1 receptor (hOT7T175, AXOR12 and GPR54) | |
| 1445 | N-Arachidonylglycine |
Novel endocannabinoid. Suppresses pain in vivo |
|
| 1446 | O-2093 |
| Inhibitor of anandamide uptake | |
| 1447 | SKF 81297 hydrobromide |
D1 agonist |
|
| 1448 | Formoterol hemifumarate |
Potent and selective b2 agonist |
|
| 1450 | Galanin (1-15) (porcine, rat) |
| Galanin receptor agonist peptide | |
| 1451 | Galanin (2-29) (rat) |
| Selective GalR2 peptide agonist | |
| 1453 | Clemastine fumarate |
| H1 antagonist | |
| 1454 | GYKI 52466 hydrochloride |
| Selective non-competitive AMPA antagonist | |
| 1455 | Orexin A (human, rat, mouse) |
| Endogenous agonist at OX1 and OX2 | |
| 1456 | Orexin B (human) |
| Endogenous agonist at OX1 and OX2 | |
| 1457 | Orexin B (mouse) |
| Endogenous agonist for orexin receptors | |
| 1458 | DAPK Substrate Peptide |
| Death associated protein kinase substrate (synthetic) | |
| 1459 | SU 4312 |
| Potent inhibitor of VEGFR tyrosine kinase | |
| 1460 | PACOCF3 |
| Phospholipase A2 inhibitor | |
| 1461 | Linomide |
| Immunomodulator with antitumour properties | |
| 1462 | AACOCF3 |
Inhibits anandamide hydrolysis |
|
| 1463 | Ghrelin (human) |
| Endogenous agonist for GHS receptor | |
| 1464 | TFLLR-NH2 |
| PAR1-activating peptide | |
| 1465 | Ghrelin (rat) |
| Endogenous agonist for GHS receptor | |
| 1466 | PPAHV |
| Non-pungent vanilloid receptor agonist | |
| 1467 | Daunorubicin hydrochloride |
| Anticancer agent | |
| 1468 | SLIGRL-NH2 |
| PAR2-activating peptide | |
| 1469 | CGP 37849 |
| Potent selective NMDA antagonist. Orally active | |
| 1470 | Flecainide acetate |
| Cardiac Na+ channel blocker. Antiarrhythmic | |
| 1471 | Etomidate |
| GABA mimetic and GABA modulatory agent | |
| 1472 | Suramin hexasodium salt |
| Non-selective P2 antagonist | |
| 1475 | (-)-[3R,4S]-Chromanol 293B |
| IKs blocker. Enantiomer of (Cat. No. 1412) | |
| 1476 | Gap 27 |
| Selective gap junction blocker | |
| 1477 | GR 127935 hydrochloride |
| Potent, selective 5-HT1B/1D antagonist | |
| 1479 | Mifepristone |
| Progesterone and glucocorticoid antagonist | |
| 1480 | FIT |
| Irreversible δ agonist | |
| 1481 | (-)-5'-DMH-CBD |
Metabolically stable anandamide transport inhibitor |
|
| 1482 | D-myo-Inositol 1,4,5-trisphosphate, hexapotassium salt |
| Ca2+ mobilising second messenger | |
| 1483 | GR 89696 fumarate |
| Subtype-selective κ opioid agonist | |
| 1484 | Oleylethanolamide |
Anandamide analogue, anorexic agent |
|
| 1485 | DEA |
Endogenous CB1 agonist |
|
| 1486 | GR 231118 |
| Potent NPY Y1 antagonist/NPY Y4 agonist. Binds to NPFF receptors | |
| 1487 | AY-NH2 |
| Selective PAR4 agonist | |
| 1488 | tcY-NH2 |
| Selective PAR4 antagonist | |
| 1489 | Mithramycin A |
| Anticancer antibiotic | |
| 1490 | MNI-caged-L-glutamate |
| Stable photoreleaser of L-glutamate | |
| 1493 | CGP 78608 hydrochloride |
| Potent, selective glycine-site NMDA antagonist | |
| 1494 | DPN |
| Highly potent ERβ agonist | |
| 1495 | Combretastatin A4 |
Inhibits tubulin polymerisation. Antitumour, antiangiogenic and antimetastatic |
|
| 1496 | SP 600125 |
| Novel and selective JNK inhibitor | |
| 1497 | Rimcazole dihydrochloride |
| σ2 antagonist. Also DAT inhibitor | |
| 1499 | CL 316243 disodium salt |
Highly selective b3 agonist |
|
| 1500 | BQ 788 sodium salt |
| Selective ETB antagonist | |
| 1495 | Combretastatin A4 |
Inhibits tubulin polymerisation. Antitumour, antiangiogenic and antimetastatic |
|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | All |
[top]